Tectonic Therapeutic Inc
TECX15.640USD
+0.580+3.85%
Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min
292.66MCap. mercado
PérdidaP/E TTM
Más Datos de Tectonic Therapeutic Inc Compañía
Tectonic Therapeutic, Inc. is a biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead program, TX000045 (TX45), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). Its second program addresses Hereditary Hemorrhagic Telangiectasia (HHT).
Información de la empresa
Símbolo de cotizaciónTECX
Nombre de la empresaTectonic Therapeutic Inc
Fecha de salida a bolsaJun 21, 2018
Director ejecutivoDr. Alise S. Reicin, M.D.
Número de empleados51
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 21
Dirección490 Arsenal Way
CiudadWATERTOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02472
Teléfono13396663320
Sitio Webhttps://tectonictx.com/
Símbolo de cotizaciónTECX
Fecha de salida a bolsaJun 21, 2018
Director ejecutivoDr. Alise S. Reicin, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Terrance G. (Terry) Mcguire
Mr. Terrance G. (Terry) Mcguire
Independent Director
Independent Director
--
--
Dr. Marc Schwabish, Ph.D.
Dr. Marc Schwabish, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Phillip B. (Phil) Donenberg
Mr. Phillip B. (Phil) Donenberg
Independent Director
Independent Director
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Alise S. Reicin, M.D.
Dr. Alise S. Reicin, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.25K
-0.30%
Dr. Peter Mcnamara, Ph.D.
Dr. Peter Mcnamara, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
19.53K
+344.82%
Dr. Praveen P. Tipirneni, M.D.
Dr. Praveen P. Tipirneni, M.D.
Independent Director
Independent Director
3.04K
--
Dr. Timothy A. (Tim) Springer, Ph.D.
Dr. Timothy A. (Tim) Springer, Ph.D.
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
IR Contact Officer
IR Contact Officer
--
--
Mr. Daniel Lochner
Mr. Daniel Lochner
Chief Financial Officer
Chief Financial Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Springer Timothy A
23.63%
Fidelity Management & Research Company LLC
14.97%
Deep Track Capital LP
7.49%
TAS Partners, L.L.C.
7.39%
EcoR1 Capital, LLC
5.00%
Otro
41.52%
Accionistas
Accionistas
Proporción
Springer Timothy A
23.63%
Fidelity Management & Research Company LLC
14.97%
Deep Track Capital LP
7.49%
TAS Partners, L.L.C.
7.39%
EcoR1 Capital, LLC
5.00%
Otro
41.52%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
27.31%
Investment Advisor
26.93%
Hedge Fund
23.57%
Corporation
10.91%
Investment Advisor/Hedge Fund
10.24%
Venture Capital
2.73%
Research Firm
1.30%
Pension Fund
0.13%
Bank and Trust
0.07%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
182
18.65M
99.86%
+1.68M
2025Q1
184
18.15M
106.94%
+1.93M
2024Q4
153
13.88M
94.13%
+369.61K
2024Q3
148
13.13M
89.69%
+166.42K
2024Q2
151
11.92M
81.47%
+8.19M
2024Q1
179
2.57M
67.87%
-1.12M
2023Q4
200
2.14M
56.67%
-1.83M
2023Q3
236
2.28M
60.58%
-1.25M
2023Q2
243
1.76M
47.84%
-1.94M
2023Q1
262
2.00M
54.58%
-1.52M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Springer Timothy A
4.42M
23.68%
+196.29K
+4.64%
Apr 11, 2025
Fidelity Management & Research Company LLC
2.80M
14.99%
+1.28M
+84.63%
Mar 31, 2025
Deep Track Capital LP
1.40M
7.51%
--
--
Mar 31, 2025
TAS Partners, L.L.C.
1.38M
7.41%
+412.50K
+42.52%
Apr 03, 2025
EcoR1 Capital, LLC
935.12K
5.01%
+85.98K
+10.13%
Mar 31, 2025
Farallon Capital Management, L.L.C.
853.05K
4.57%
+140.00K
+19.63%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
186.07K
1%
+17.21K
+10.20%
Mar 31, 2025
Polaris Partners
657.98K
3.52%
-500.00K
-43.18%
Apr 03, 2025
The Vanguard Group, Inc.
361.17K
1.93%
+120.00
+0.03%
Mar 31, 2025
5AM Ventures
511.66K
2.74%
-85.00K
-14.25%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Fecha
Tipo
Relación
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
Jun 18, 2024
Merger
12→1
